LLS TAP: European Partners Dream Big, Make Bold Progress

“We were one of the first European companies collaborating with TAP. Through TAP, the door opens to some of the top-notch, world-class US clinical centers, which we needed in order to navigate the biology starting from Waldenstroms disease to T cell lymphoma and now AML.” 

Tim Van Hauwermeiren, CEO argenx
(Quote from Value Creation for Companies through LLS TAP: Dollars & Beyond, December 2020)

Please join The Leukemia & Lymphoma Society's (LLS) Therapy Acceleration Program® (TAP) for a live one-hour discussion panel.

Hear from LLS TAP staff and TAP European biotech partners who are dreaming big and making bold progress for blood cancer patients. 


  • Introduction
  • Moderated discussion with European TAP portfolio partners:
    • Affimed (Germany)
    • Faron Pharmaceuticals (Finland)
    • ImCheck Therapeutics (France)
    • Ryvu Therapeutics (Poland)
  • Q&A


Wednesday, Jan. 18, 2023

12 noon EST/9 am PST
via Zoom


Register to learn more. 

Follow LLS